Id: acc2298
Group: 2sens
Protein: NDRG-1
Gene Symbol: NDRG1
Protein Id: Q92597
Protein Name: NDRG1_HUMAN
PTM: phosphorylation
Site: Thr346
Site Sequence: LDGTRSRSHTSEGTRSRSHTS
Disease Category: Cancer
Disease: Myeloma
Disease Subtype: multiple myeloma
Disease Cellline: BR bortezomib-resistant 8226
Disease Info:
Drug: bortezomib
Drug Info: "Bortezomib is a reversible and selective proteasome inhibitor targeting the 20S proteasome with a Ki of 0.6 nM, used for the treatment of multiple myeloma in patients who have received at least two prior therapies and demonstrated disease progression on the last therapy. "
Effect: resist
Effect Info: "During exposure to bortezomib, the phosphorylation of NDRG-1 in parental/control multiple myeloma cells is rapidly upregulated. SGK inhibitors can significantly enhance bortezomib-induced apoptosis in cell lines and primary multiple myeloma cells."
Note:
Score: 5.0
Pubmed(PMID): 26869290
Sentence Index:
Sentence:

Sequence & Structure:

MSREMQDVDLAEVKPLVEKGETITGLLQEFDVQEQDIETLHGSVHVTLCGTPKGNRPVILTYHDIGMNHKTCYNPLFNYEDMQEITQHFAVCHVDAPGQQDGAASFPAGYMYPSMDQLAEMLPGVLQQFGLKSIIGMGTGAGAYILTRFALNNPEMVEGLVLINVNPCAEGWMDWAASKISGWTQALPDMVVSHLFGKEEMQSNVEVVHTYRQHIVNDMNPGNLHLFINAYNSRRDLEIERPMPGTHTVTLQCPALLVVGDSSPAVDAVVECNSKLDPTKTTLLKMADCGGLPQISQPAKLAEAFKYFVQGMGYMPSASMTRLMRSRTASGSSVTSLDGTRSRSHTSEGTRSRSHTSEGTRSRSHTSEGAHLDITPNSGAAGNSAGPKSMEVSC

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
NDRG1-Thr346
Cancer Intensity
BRCA
COAD -0.935
HGSC 1.054
ccRCC
GBM
HNSC -0.119
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
T 346 U Alzheimer's disease Phosphorylation 23363009
T 346 U Clear cell kidney cancer Phosphorylation 37298315
T 346 U Triple-negative breast cancer Phosphorylation 36594086

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: